Stonepine Capital Management LLC purchased a new position in Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,132,388 shares of the company's stock, valued at approximately $3,680,000. Inhibikase Therapeutics makes up 3.0% of Stonepine Capital Management LLC's investment portfolio, making the stock its 12th biggest holding. Stonepine Capital Management LLC owned 1.63% of Inhibikase Therapeutics as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently modified their holdings of the company. Blair William & Co. IL boosted its stake in Inhibikase Therapeutics by 7.0% during the fourth quarter. Blair William & Co. IL now owns 134,953 shares of the company's stock valued at $439,000 after buying an additional 8,833 shares in the last quarter. Stifel Financial Corp purchased a new stake in shares of Inhibikase Therapeutics during the fourth quarter valued at $43,000. Jefferies Financial Group Inc. purchased a new stake in shares of Inhibikase Therapeutics during the fourth quarter valued at $48,000. Alpine Global Management LLC purchased a new stake in shares of Inhibikase Therapeutics during the fourth quarter valued at $48,000. Finally, Caxton Corp purchased a new stake in shares of Inhibikase Therapeutics during the fourth quarter valued at $53,000. Institutional investors own 3.81% of the company's stock.
Inhibikase Therapeutics Trading Down 1.0%
IKT stock traded down $0.02 during mid-day trading on Wednesday, hitting $1.97. The stock had a trading volume of 90,400 shares, compared to its average volume of 232,655. The stock has a market capitalization of $146.45 million, a price-to-earnings ratio of -0.74 and a beta of 1.01. The company has a fifty day moving average of $2.09 and a 200 day moving average of $2.48. Inhibikase Therapeutics, Inc. has a 1-year low of $1.12 and a 1-year high of $4.20.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a "neutral" rating on shares of Inhibikase Therapeutics in a research note on Friday, March 28th.
Get Our Latest Stock Analysis on Inhibikase Therapeutics
Inhibikase Therapeutics Profile
(
Free Report)
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
Recommended Stories
Before you consider Inhibikase Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.
While Inhibikase Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
